Analyst Ratings February 13, 2026

Leggett & Platt Shares Drop After Mixed Q4; Piper Sandler Keeps Neutral Call

Company posts a narrow EPS miss, revenue beat and guidance largely in line with expectations as industry headwinds and customer losses weigh on Bedding segment

By Sofia Navarro LEG
Leggett & Platt Shares Drop After Mixed Q4; Piper Sandler Keeps Neutral Call
LEG

Leggett & Platt (NYSE: LEG) saw its stock decline roughly 7% after releasing fourth-quarter results that narrowly missed earnings expectations while modestly exceeding revenue estimates. Piper Sandler retained a Neutral rating and a $12 price target, calling the sell-off exaggerated and attributing it to new investor volatility. Key valuation metrics and the company’s long dividend record remain notable to income-focused investors.

Key Points

  • Leggett & Platt reported adjusted Q4 EPS of $0.22, narrowly missing the $0.23 estimate while posting $939 million in revenue, a slight beat.
  • Piper Sandler maintained a Neutral rating and a $12 price target, calling the ensuing share sell-off exaggerated and likely driven by new investor volatility.
  • Company valuation and cash metrics highlighted include a P/E of 7.34, a free cash flow yield of 18%, and 55 consecutive years of dividend payments; the stock has returned 22.2% over the past six months.

Leggett & Platt (NYSE: LEG) experienced a roughly 7% decline in its share price following the release of fourth-quarter results, even though Piper Sandler kept its Neutral rating and maintained a $12.00 price target on the stock.

The bedding and furniture components manufacturer reported an adjusted fourth-quarter earnings per share of $0.22, which was a hair below the $0.23 analysts had forecast. At the same time, the company delivered revenue of $939 million for the quarter, slightly above consensus estimates. Investors reacted to the mixed outcome with a notable sell-off despite the revenue beat.

Market data referenced in the company analysis shows LEG trading at a price-to-earnings ratio of 7.34, a level that some market participants view as suggesting potential undervaluation relative to its InvestingPro Fair Value. The company’s free cash flow yield was highlighted at 18%, and the record of sustained shareholder payouts is significant: Leggett & Platt has paid dividends for 55 consecutive years.


Earnings drivers and margins

Leggett & Platt’s consolidated gross profit margin stood at 18.35% in the period reported, reflecting ongoing pressures in the operating environment for the company’s product lines. Management noted that the broader mattress industry experienced low-single-digit percentage declines in 2025 and that the company expects the industry to see flat to low-single-digit percentage growth in 2026.

Despite that industry outlook, Leggett & Platt warned that its Bedding segment is likely to lag the overall mattress market. Company commentary attributed the expected underperformance to customer consolidation headwinds that began in the fourth quarter and to continuing impacts from customer losses.


Guidance and potential upside

The firm’s guidance for 2026 was described as generally in line with consensus expectations. Management also identified a potential upside scenario tied to an improving macroeconomic backdrop. Separately, the company noted that its U.S. Spring business appears to be seeing a mix shift toward higher-end products, which could be a source of relative strength within Bedding if that trend continues.

On the proposed SGI acquisition, company leadership did not take questions during the earnings call, citing a standing non-disclosure agreement and a six-month standstill period, leaving details around that transaction limited in the public discussion.


Analyst reaction and investor takeaways

Piper Sandler characterized the post-earnings sell-off as "exaggerated" and suggested it was driven by new investor volatility rather than a reappraisal of long-term fundamentals. The $12 price target that Piper Sandler has retained implies roughly 11 times the firm’s 2027 earnings per share estimate, according to the firm’s model.

Investment research notes emphasize LEG’s current price sits below its InvestingPro Fair Value, and with analysts forecasting the company to be profitable this year, some value-oriented investors may view the situation as an opportunity. The stock has posted a 22.2% price return over the past six months, indicating recent positive momentum despite the immediate reaction to the quarter.


Context for investors

While the quarter combined a narrow EPS miss with a modest revenue beat, the mix of results and the specific headwinds cited for the Bedding segment have prompted close attention from investors and analysts. The company’s capital return history and cash flow metrics remain points of interest, but uncertainty around customer consolidation, segment-level performance and the timing and details of the proposed SGI transaction are variables market participants will watch.

Subscribers to InvestingPro are able to access additional ProTips and a more detailed financial report that expands on the metrics summarized here.

Risks

  • Bedding segment underperformance tied to customer consolidation and ongoing customer losses - impacts bedding and furniture manufacturing sectors.
  • Gross profit margin pressure at 18.35% amid challenging operating conditions - impacts company profitability and manufacturing margins.
  • Uncertainty around the proposed SGI acquisition due to a non-disclosure agreement and a six-month standstill restricts visibility on potential strategic effects - impacts corporate strategy and M&A outlook.

More from Analyst Ratings

HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026